bluebird bio
$30.229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$30.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.88 (-2.83%) As of 5:18 PM UTC today
Why Robinhood?
You can buy or sell bluebird bio and other stocks, options, and ETFs commission-free!
About BLUE
bluebird bio, Inc. Common Stock, also called bluebird bio, is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA. The listed name for BLUE is bluebird bio, Inc. Common Stock.
CEO
Nick Leschly
Employees
1,213
Headquarters
Cambridge, Massachusetts
Founded
1992
Market Cap
1.85B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
6.02M
High Today
$32.06
Low Today
$29.60
Open Price
$31.43
Volume
1.71M
52 Week High
$76.00
52 Week Low
$24.24
Analyst Ratings
32%
of 22 ratings
Buy
32%
Hold
68%
Sell
0%
BLUE Earnings
-$4.04
-$2.69
-$1.35
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$2.92 per share
Actual
-$3.01 per share